Biotech company Eradivir is developing lead drug EV25 to treat influenza

Contributed by: GlobeNewswire

Tags

pharmaceuticals

More Like This

NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun

Kindeva Drug Delivery and Emervax Partner To Bring Game Changing Vaccine Administration to Patients

Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company

ViiV Healthcare to present data for its next generation of ultra long-acting treatments for HIV

PR Newswire associated0

Centivax Selects Global CDMO BioCina to Initiate cGMP Manufacturing of Revolutionary Universal Influenza Vaccine

Exscientia Receives Open Philanthropy Grant to Explore New Therapeutic Approach for Pandemic Influenza

ViiV Healthcare Announces Interim Data at CROI Indicating Superior Efficacy of Long-Acting Injectable HIV Treatment Cabenuva (Cabotegravir + Rilpivirine) Compared to Daily Oral Therapy in Individuals Living With HIV Who Have Adherence Challenges

FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025